[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preoperative-evaluation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preoperative-evaluation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100614679","awareness-of-surgeons-100614679",false,"NCT07282730","Awareness of Surgeons","Evaluation of Surgical Physicians' Awareness of Preoperative Patient Preparation","Inclusion Criteria:\n\n* Individuals who voluntarily approved the participation form,\n* Those who fully participated in the training and testing.\n\nExclusion Criteria:\n\n* Those who did not complete the voluntary consent form,\n* Those who did not participate in any phase of the training or testing,\n* Participants with incomplete or inaccurate data.",true,"ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","It aims to objectively reveal the current knowledge levels of surgical physicians, to increase their awareness, and to contribute to in-house training processes with the results obtained and to fill an important gap in the literature.",[25,26],"Awareness of Surgeon","Preoperative Evaluation","NOT_YET_RECRUITING","2025-12-14",{"date":30,"type":31},"2025-12-19","ACTUAL",{"date":33,"type":21},"2025-12-10",{"date":35,"type":21},"2025-12-31",{"name":37,"class":38},"Istinye University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100608956","real-world-study-on-preoperative-application-of-rezvilutamide-100608956","NCT07208292","Real-world Study on Preoperative Application of Rezvilutamide","RWS-GU001","Inclusion Criteria:\n\n* Pathological confirmation: Confirmed as prostate adenocarcinoma by ultrasound\u002FMRI-guided prostate biopsy, with ISUP grade ≥ 2 (Gleason score ≥ 7);\n* Clinical staging (based on AJCC 8th edition):High-risk localized: cT3a or PSA \\> 20 ng\u002Fml or Gleason score ≥ 8;Locally advanced: cT3b-4 or positive pelvic lymph nodes (cN1);\n* Surgical feasibility: Multidisciplinary team (MDT) assessment considers that R0\u002FR1 resection can be achieved;\n* Laboratory requirements:Hemoglobin ≥ 90 g\u002FL, platelets ≥ 100×10\\^9\u002FL;Liver function: ALT\u002FAST ≤ 2.5×ULN, bilirubin ≤ 1.5×ULN;Renal function: eGFR ≥ 30 mL\u002Fmin\u002F1.73m².\n\nExclusion Criteria:\n\n* Disease-related: Distant metastasis (M1, including bone metastasis or visceral metastasis);Pathology indicating neuroendocrine differentiation or small cell carcinoma component \\> 10%;\n* Treatment-related:Previous history of receiving radiotherapy, cryotherapy, or systemic chemotherapy for prostate cancer;History of other malignant tumors within 5 years (except non-melanoma skin cancer);\n* Comorbidities: Uncontrolled cardiovascular diseases (e.g., NYHA Class III heart failure, myocardial infarction within 6 months);History of severe epilepsy (requiring long-term use of anticonvulsant drugs);・Others:Known allergy to relugolix or LHRH analogs;Participation in other interventional clinical trials.","MALE",{"count":49,"type":21},115,"1 Year","Real-world study on Preoperative Application of Rezvilutamide",[26],[54],"prostate cancer","2025-09-26",{"date":57,"type":31},"2025-10-06",{"date":59,"type":21},"2025-10-15",{"date":61,"type":21},"2027-07-15",{"name":63,"class":38},"Shanghai Pudong New Area Gongli Hospital"]